The table below details the trials that are currently accruing patients.
|ACTICCA-1- Gallbladder carcinoma||0||50|
|ALT-GIST- GI Stromal Tumour||57||240|
|ASCOLT – Colorectal cancer||92||300|
|CONTROL NETs – NeuroEndocrine Tumour||42||73|
|INTERAACT – Anal cancer||64||80|
|INTEGRATE II – Gastro-Oesophageal||1||350|
|NABNEC – NeuroEndocrine Tumour||1||70|
|TOP GEAR – Stomach cancer||330||752|
Recruitment figures to end January 2017.
The AGITG has a new study now open to recruitment:
INTEGRATE II: A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC).
Status: ANZ central ethics approval was obtained in March 2016, and in September 2016 for the protocol amendment. INTEGRATE II site selection has been completed in ANZ, Korea, and Taiwan and start-up procedures are underway in those regions. A total of up to 82 sites are to be activated on the study – 28 ANZ, 12 Korea, 12 Japan, 5 Taiwan, 15 Canadian and 10 United States sites. The first ANZ site opened at Townsville Hospital, QLD early October, with remaining ANZ sites opening in November/December and Q1 2017. Asian & North American sites are expected to activate from December 2016 through Q1/Q2 2017. Investigator Meetings were held in October for ANZ and Asian sites, with Canadian investigators meeting tentatively scheduled for late November.
Trial Results Lay Summaries (click on the links below):